STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8+ T-Cell Dysfunction in NSCLC-Reference-Cited by-同舟云学术

STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8+ T-Cell Dysfunction in NSCLC

Published:2023-12 Issue:12 Volume:18 Page:1714-1730
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Li Anlin,Wang Yuanyuan,Yu Zhixin,Tan Zihui,He Lina,Fu Sha,Shi Mengting,Du Wei,Luo Linfeng,Li Zhichao,Liu Jiaqing,Zhou Yixin,Fang Wenfeng,Yang Yunpeng,Zhang Li,Hong Shaodong

Funder

National Natural Science Foundation of China

Fundamental Research Funds for the Central Universities

National Natural Science Foundation of China-Guangdong Joint Fund

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference61 articles.

1. Predictive biomarkers for checkpoint inhibitor-based immunotherapy;Gibney;Lancet Oncol,2016

2. Wedding of molecular alterations and immune checkpoint blockade: genomics as a matchmaker;Fountzilas;J Natl Cancer Inst,2021

3. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression;Shackelford;Nat Rev Cancer,2009